Here is the design of a clinical trial:

Official Title: Efficacy, Safety and Cost-effectiveness of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis: a Randomized, Parallel 3 Arms, Active-controlled, Phase 3 Open Label With Blinded Outcome Assessment Study

Included conditions:
- Uveitis

Study Armgroups:
- {'label': 'Adalimumab', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Adalimumab']}
- {'label': 'Methotrexate', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Methotrexate']}
- {'label': 'Adalimumab+Methotrexate', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Adalimumab+Methotrexate']}

Interventions:
- {'type': 'DRUG', 'name': 'Methotrexate', 'description': 'Inicial dose 15mg/week increasing up to 25 mg/week', 'armGroupLabels': ['Methotrexate']}
- {'type': 'DRUG', 'name': 'Adalimumab', 'description': 'At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.', 'armGroupLabels': ['Adalimumab']}
- {'type': 'DRUG', 'name': 'Adalimumab+Methotrexate', 'description': 'Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.\n\nMethotrexate:Inicial dose 15mg/week increasing up to 25 mg/week', 'armGroupLabels': ['Adalimumab+Methotrexate']}

Primary Outcomes:
- {'measure': 'Good Clinical Response', 'description': 'Complete resolution of the ocular inflammatory signs, achieved within the first 16 weeks of the study, and maintained until week 52; no treatment failure due to safety or intolerability.', 'timeFrame': '52 weeks'}

Please estimate the sample size based on the assumption: 
Significance level: 0.05; Power: 80%; Missing/dropout rate: 15%; Superiority or relevant clinical improvement: delta of 5% of the effect.
Sample size determination
          
ADA arm: after 1âyear (50 weeks) of treatment, 20.3% of NIU patients achieved an outcome similar to our primary efficacy outcome.28

          
MTX arm: after 6 months of treatment, 65% of NIU patients achieve also similar outcome;64 we estimate that of those patients, 18%65 and 16%66 will be unable to maintain our outcome due to AEs and inefficacy, respectively; therefore, at 1âyear, 43% will achieve our primary efficacy outcome. This figure will be assumed as the percentage of subjects treated with monotherapy achieving the primary efficacy outcome.
          
MTX+ADA arm: we will assume that combination therapy will increase the percentage of subjects achieving our primary efficacy outcome by 23% compared with the monotherapy arms.
          To detect statistically significant differences between groups with a power of 80% and a significance level of 0.05, it will be necessary to recruit 54 patients per study arm (162 in total). Since the follow-up period is 52 weeks, losses of 15% will be assumed, increasing the sample size to 64 patients per study arm (192 patients in total). In order to test the difference between the treatments, superiority or relevant clinical improvement has been considered from a delta of 5% of the effect.